Kratom
Rayna Sharma 1 , Jo Barnes
1 *
+ Author Affiliations
- Author Affiliations
1 School of Pharmacy, University of Auckland, PB 92019, Auckland, New Zealand.
* Correspondence to: j.barnes@auckland.ac.nz
Journal of Primary Health Care 14(3) 288-290 https://doi.org/10.1071/HC22110
Published: 20 September 2022
© 2022 The Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)
References
[1] Kratom – not such a nice cup of tea. Prescriber Update 2021; 42 52–53. Available at https://www.medsafe.govt.nz/profs/PUArticles/December2021/Kratom-not-such-a-nice-cup-of-tea.html [accessed 23 July 2022][2] Hartley C, Bulloch M, Penzak SR. Clinical pharmacology of the dietary supplement kratom (Mitragyna speciosa). J Clin Pharmacol 2022; 62 577–593.
| Clinical pharmacology of the dietary supplement kratom (Mitragyna speciosa).Crossref | GoogleScholarGoogle Scholar |
[3] Prevete E, Kuypers KPC, Theunissen EL, et al. A systematic review of pre(clinical) studies on the therapeutic potential and safety profile of kratom in humans. Hum Psychopharmacol Clin Exp 2022; 37 e2805
| A systematic review of pre(clinical) studies on the therapeutic potential and safety profile of kratom in humans.Crossref | GoogleScholarGoogle Scholar |
[4] World Health Organization. Pre-review report: Kratom (Mitragyna speciosa), mitragynine, and 7-hydroxymitragynine. Expert Committee on Drug Dependence, 44th Meeting, Geneva, 11–15 October 2021. 2021. Available at https://cdn.who.int/media/docs/default-source/controlled-substances/unedited--advance-copy-44th-ecdd-review-report_kratom.pdf?sfvrsn=8d699207_8&download=true [accessed 25 July 2022].
